Evidence map›Paper›PMID 24132387›Full record

ReviewEuropean journal of pediatrics2014

Pathological fractures in paediatric patients with inflammatory bowel disease.

Sze Choong Wong, A G Anthony Catto-Smith, Margaret Zacharin

Registry-linked trialAbstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in European journal of pediatrics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02470663 (Bone Density in Children With IBD Treated With Amorphous Calcium or Commercial Crystalline Calcium), which is not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02470663 nawithdrawnnot on this mapstarted 2015, after this paper: background citation

Bone Density in Children With IBD Treated With Amorphous Calcium or Commercial Crystalline Calcium: A Prospective Randomized Multicenter Trial

TypeinterventionalSponsorSheba Medical CenterRan2015 to 2017Enrolled0ConditionsInflammatory Bowel DiseaseArmsDENSITYTM caplets (marketed as Amorphical), Calcium carbonate 600 mg once daily
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Management of primary and secondary osteoporosis in children.Therapeutic advances in musculoskeletal disease · 2020
    Review
  7. Suppressor of cytokine signaling 2 (Disease models & mechanisms · 2018
    Article
  8. Musculoskeletal health in newly diagnosed children with Crohn's disease.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2017
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Sze Choong WongDepartment of Endocrinology, The Royal Children's Hospital, Flemington Road, Parkville, 3052, Melbourne, Australia, jarod.wong@rch.org.au.
A G Anthony Catto-Smith
Margaret Zacharin
Royal Ottawa Mental Health Centre · CAUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledPaediatric inflammatory bowel disease (IBD), especially Crohn's disease (CD), is commonly associated with poor skeletal health, related to the direct effects of chronic inflammation, prolonged use of glucocorticoid (GC), poor nutrition, delayed puberty and low muscle mass. Low bone mineral density is commonly reported, although the prevalence of long bone fractures may not be increased in these patients. Emerging evidence however suggests that there may be an increased risk of vertebral fractures (VFs) in this group. VFs presenting at diagnosis of paediatric CD, prior to any GC exposure, have been reported, highlighting the deleterious effect of inflammation on skeletal health. This paper reviews the published literature on pathophysiology of skeletal morbidity and fractures in paediatric IBD, illustrated with a new case report of multiple VFs in a prepubertal girl with CD, soon after diagnosis, who received minimal amounts of oral GC. Optimising control of disease, addressing vitamin D deficiency, encouraging physical activity and ensuring normal growth and pubertal progression are paramount to management of bone health in these patients. Despite the lack of evidence, there may be a place for bisphosphonate treatment, especially in the presence of symptomatic pathological fractures, but this requires close monitoring by clinicians with expertise in paediatric bone health.

conclusionChronic inflammation mediated by pro-inflammatory cytokines may have adverse effects on skeletal health in paediatric patients with IBD. The risk of vertebral fractures may be increased, even without exposure to glucocorticoid. Clinical monitoring of these patients requires careful attention to the various factors that impact on bone health.

Indexed as

AdolescentBody HeightBody WeightBone DensityChildColitis, UlcerativeCrohn DiseaseDiphosphonatesFractures, SpontaneousHumansMass ScreeningMethylprednisolonePrednisolonePuberty, DelayedRisk FactorsSpinal FracturesDiphosphonatesMethylprednisolonePrednisolone

Identifiers

PMID24132387
OpenAlexW2017310059

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.